<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We determined the effects of aspirin and a novel <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi>/<z:chebi fb="11" ids="26333">prostaglandin</z:chebi> endoperoxide (TP)-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BMS-180291, on <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:mp ids='MP_0001914'>bleeding</z:mp> times in skin and mesenteric arteries </plain></SENT>
<SENT sid="1" pm="."><plain>In anesthetized rats, occlusive <z:mp ids='MP_0005048'>thrombosis</z:mp> was induced in the carotid artery by topical application of <z:chebi fb="0" ids="30812">ferrous chloride</z:chebi> and in the vena cava by blood flow stasis combined with either infusion of thromboplastin or hypotonic saline </plain></SENT>
<SENT sid="2" pm="."><plain>Aspirin (1, 10, and 50 mg/kg) did not reduce arterial or venous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight significantly </plain></SENT>
<SENT sid="3" pm="."><plain>BMS 180,291 (150 micrograms/kg/min) decreased arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight and hypotonic saline-induced caval <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight by 58 and 57%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>BMS-180291 lacked antithrombotic activity at a lower dose (50 micrograms/kg/min) and failed to inhibit thromboplastin-induced caval <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>BMS-180291 (150 micrograms/kg/min) significantly reduced arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight by 40% when plasma <z:chebi fb="2" ids="28918">epinephrine</z:chebi> concentration was increased to 5 ng/ml </plain></SENT>
<SENT sid="6" pm="."><plain>BMS-180291 and aspirin produced increases of only &lt; or = 30% in <z:mp ids='MP_0001914'>bleeding</z:mp> times </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that BMS-180291 has antithrombotic activity in experimental aspirin-resistant arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Both aspirin and BMS-180291 have only modest effects on small artery hemostasis in rats </plain></SENT>
</text></document>